One of only two cases to go to trial in New Jersey in litigation involving the bone loss drug Zometa has been settled on unknown terms before a state appeals court could issue a ruling.
A three-judge Appellate Division panel had been expected to decide whether to affirm or reverse the no-cause verdict won by Novartis against plaintiff Beverly Meng. The court announced April 9 that “the issues in the dispute have been amicably resolved.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]